SEC 13F Intelligence

Trails Edge Capital Partners, LP / 430

Trails Edge Capital Partners, LP’s Terns Pharmaceuticals Inc Position

Does Trails Edge Capital Partners, LP own Terns Pharmaceuticals Inc (430)? Not currently — the last reported position was 300.0K shares worth $12M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$12M
Q4 2025
Shares
300.0K
% of Portfolio
+2.99%
Quarters Held
1
position exited

Position History 430

Reported value by quarter
Q4 ’25: $12MQ4 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q4 2025300.0K$12M+2.99%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Trails Edge Capital Partners, LP’s full portfolio or all institutional holders of 430.